Terms: = Liver cancer AND HIF1A, Q16665, 3091, ENSG00000100644, MOP1, HIF1-ALPHA, PASD8, HIF-1alpha AND Clinical Outcome
15 results:
1. Selenium Nanoparticles Show Anticancer Activity Through Regulation of HIF-1α and HIF-2α Under Hypoxic Condition in liver cancer Cells.
Acharya S; Nithyananthan S; Thirunavukkarasu C
DNA Cell Biol; 2023 Jul; 42(7):433-444. PubMed ID: 37219890
[TBL] [Abstract] [Full Text] [Related]
2. Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: cancer Metabolism and Immune Status.
Iseda N; Itoh S; Yoshizumi T; Tomiyama T; Morinaga A; Yugawa K; Shimokawa M; Shimagaki T; Wang H; Kurihara T; Kitamura Y; Nagao Y; Toshima T; Harada N; Kohashi K; Baba S; Ishigami K; Oda Y; Mori M
Hepatol Commun; 2022 Apr; 6(4):665-678. PubMed ID: 34687175
[TBL] [Abstract] [Full Text] [Related]
3. Angiogenesis Genotyping and clinical outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study.
Faloppi L; Puzzoni M; Casadei Gardini A; Silvestris N; Masi G; Marisi G; Vivaldi C; Gadaleta CD; Ziranu P; Bianconi M; Loretelli C; Demurtas L; Lai E; Giampieri R; Galizia E; Ulivi P; Battelli N; Falcone A; Cascinu S; Scartozzi M
Target Oncol; 2020 Feb; 15(1):115-126. PubMed ID: 32020517
[TBL] [Abstract] [Full Text] [Related]
4. Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.
De Matteis S; Scarpi E; Granato AM; Vespasiani-Gentilucci U; La Barba G; Foschi FG; Bandini E; Ghetti M; Marisi G; Cravero P; Gramantieri L; Cucchetti A; Ercolani G; Santini D; Frassineti GL; Faloppi L; Scartozzi M; Cascinu S; Casadei-Gardini A
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30917505
[TBL] [Abstract] [Full Text] [Related]
5. Inhibition of caspase-9 aggravates acute liver injury through suppression of cytoprotective autophagy.
Guo R; Lin B; Pan JF; Liong EC; Xu AM; Youdim M; Fung ML; So KF; Tipoe GL
Sci Rep; 2016 Sep; 6():32447. PubMed ID: 27580936
[TBL] [Abstract] [Full Text] [Related]
6. Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma.
Lee HG; Kim H; Son T; Jeong Y; Kim SU; Dong SM; Park YN; Lee JD; Lee JM; Park JH
Oncotarget; 2016 Jul; 7(27):41798-41810. PubMed ID: 27260001
[TBL] [Abstract] [Full Text] [Related]
7. Biological and Prognostic Significance of the Morphological Types and Vascular Patterns in Colorectal liver Metastases (CRLM): Looking Beyond the Tumor Margin.
Siriwardana PN; Luong TV; Watkins J; Turley H; Ghazaley M; Gatter K; Harris AL; Hochhauser D; Davidson BR
Medicine (Baltimore); 2016 Feb; 95(8):e2924. PubMed ID: 26937938
[TBL] [Abstract] [Full Text] [Related]
8. SNP rs2057482 in hif1a gene predicts clinical outcome of aggressive hepatocellular carcinoma patients after surgery.
Guo X; Li D; Chen Y; An J; Wang K; Xu Z; Chen Z; Xing J
Sci Rep; 2015 Jun; 5():11846. PubMed ID: 26115041
[TBL] [Abstract] [Full Text] [Related]
9. β-Carotene inhibits neuroblastoma cell invasion and metastasis in vitro and in vivo by decreasing level of hypoxia-inducible factor-1α.
Kim YS; Lee HA; Lim JY; Kim Y; Jung CH; Yoo SH; Kim Y
J Nutr Biochem; 2014 Jun; 25(6):655-64. PubMed ID: 24746828
[TBL] [Abstract] [Full Text] [Related]
10. The correlation of expression levels of HIF-1α and HIF-2α in hepatocellular carcinoma with capsular invasion, portal vein tumor thrombi and patients' clinical outcome.
Yang SL; Liu LP; Jiang JX; Xiong ZF; He QJ; Wu C
Jpn J Clin Oncol; 2014 Feb; 44(2):159-67. PubMed ID: 24374892
[TBL] [Abstract] [Full Text] [Related]
11. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic significance of HIF-1α expression in hepatocellular carcinoma: a meta-analysis.
Zheng SS; Chen XH; Yin X; Zhang BH
PLoS One; 2013; 8(6):e65753. PubMed ID: 23799043
[TBL] [Abstract] [Full Text] [Related]
13. The expression of HIF-1α in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome.
Xiang ZL; Zeng ZC; Fan J; Tang ZY; He J; Zeng HY; Chang JY
Mol Biol Rep; 2012 Feb; 39(2):2021-9. PubMed ID: 21647551
[TBL] [Abstract] [Full Text] [Related]
14. Deregulation of hif1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue--influence of a modulated host stroma on the prognosis of HCC.
Simon F; Bockhorn M; Praha C; Baba HA; Broelsch CE; Frilling A; Weber F
Langenbecks Arch Surg; 2010 Apr; 395(4):395-405. PubMed ID: 20165955
[TBL] [Abstract] [Full Text] [Related]
15. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer.
Mackay H; Hedley D; Major P; Townsley C; Mackenzie M; Vincent M; Degendorfer P; Tsao MS; Nicklee T; Birle D; Wright J; Siu L; Moore M; Oza A
Clin Cancer Res; 2005 Aug; 11(15):5526-33. PubMed ID: 16061869
[TBL] [Abstract] [Full Text] [Related]
